Astellas Pharma reached a settlement with Lupin and Zydus in the Myrbetriq\u00ae patent infringement lawsuit, receiving a total of USD 60 million in settlement payments and USD 150 million in upfront license fees.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4503","jir_company_name":"Astellas Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-02-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4503-20260212-01.pdf","jir_short_summary":"Astellas Pharma reached a settlement with Lupin and Zydus in the Myrbetriq\u00ae patent infringement lawsuit, receiving a total of USD 60 million in settlement payments and USD 150 million in upfront license fees.","jir_summary":"### Overview of Settlement Agreement\nAstellas Pharma entered into a settlement agreement with Lupin Limited and Zydus Lifesciences Limited regarding the United States patent infringement lawsuit related to Myrbetriq\u00ae, an overactive bladder treatment. Under the settlement, the two companies will pay a total of USD 60 million in settlement payments and USD 150 million in upfront license fees, as well as license fees per unit of the relevant products. This resolves all litigation concerning Myrbetriq\u00ae.\n\n### Future Outlook and Impact\nThe impact of this settlement on the full-year consolidated results for the fiscal year ending March 2026 is currently under review, and details have not been disclosed. While specific financial figures related to future earnings are unknown, receipt of settlement payments and license fees is expected to have a positive financial effect.","jir_financial_highlights":"Settlement payment received: USD 60 million (Unknown)\nUpfront license fee: USD 150 million (Unknown)\nImpact on full-year consolidated results: Unknown (Under review)","jir_category":"","jir_hashtags":"#AstellasPharma, #PatentLawsuitSettlement, #general_ir, #JapaneseStocks","jir_key_figures":"Settlement payment received: USD 60 million\nUpfront license fee: USD 150 million\nImpact on full-year consolidated results: Under review","jir_meta_title":"Astellas Pharma Settles Myrbetriq\u00ae Patent Infringement Lawsuit with Lupin and Zydus, Receiving Approximately USD 210 Million","jir_meta_description":"Astellas Pharma has settled the Myrbetriq\u00ae patent infringement lawsuit with Lupin and Zydus, receiving a total of USD 60 million in settlement payments and USD 150 million in license fees. The impact on full-year earnings is under review.","jir_og_title":"Astellas Pharma Settles Myrbetriq\u00ae Patent Infringement Lawsuit","jir_og_description":"Astellas Pharma announced a settlement of the patent lawsuit with Lupin and Zydus, receiving approximately USD 210 million.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6911,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-27439","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n